DDInter1327 DDInter1376
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Olaparib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Olaparib {u} may lead to a major life threatening interaction when taken with {v} Voriconazole
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Olaparib may lead to a major life threatening interaction when taken with Tucatinib
Olaparib may lead to a major life threatening interaction when taken with Voriconazole